Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay.
We compared rifabutin susceptibility and rpoB mutations in 98 multi-drug-resistant strains of Mycobacterium tuberculosis (MDR-TB) by DNA sequencing and with a line probe assay using the commercially available INNO-LiPA Rif. TB kit (the LiPA). Our results indicated that rifabutin continues to remain active against MDR-TB strains harboring certain genetic alterations and also that the LiPA might be useful in identifying MDR-TB strains susceptible to rifabutin.
Yoshida
Shiomi
S
Clinical Research Center, National Hospital Organization, Kinki-chuo Chest Medical Center, 1180 Nagasone-cho, Sakai, 591-8555, Japan. dustin@kch.hosp.go.jp
Suzuki
Katsuhiro
K
Iwamoto
Tomotada
T
Tsuyuguchi
Kazunari
K
Tomita
Motohisa
M
Okada
Masaji
M
Sakatani
Mitsunori
M
D000904:Antibiotics, Antitubercular / Q000494:pharmacology; D001426:Bacterial Proteins / Q000235:genetics*; D004252:DNA Mutational Analysis / Q000379:methods; D012321:DNA-Directed RNA Polymerases; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D009154:Mutation / Q000235:genetics; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics*; D009693:Nucleic Acid Hybridization / Q000379:methods; D017828:Rifabutin / Q000494:pharmacology*; D018088:Tuberculosis, Multidrug-Resistant / Q000235:genetics* / Q000382:microbiology*
D000904:Antibiotics, Antitubercular; D001426:Bacterial Proteins; C505805:rpoB protein, Mycobacterium tuberculosis; D017828:Rifabutin; D012321:DNA-Directed RNA Polymerases